NewLink Genetics price target raised to $35 from $23 at Canaccord Canaccord is more optimistic that the P3 IMPRESS trial of HyperAcute Pancreas in resected pancreatic cancer could meet its primary endpoint of an improvement in overall survival vs. placebo following a management meeting. Shares are Buy rated.
News For NLNK From The Last 14 Days
Check below for free stories on NLNK the last two weeks.
NewLink pancreatic cancer vaccine a 'long shot,' says Summer Street After hosting a conference call, Summer Street calls NewLink Genetics' vaccine for pancreatic cancer a "long shot." The firm says it doubts the phase III testing will be successful.